Infographic: Efficacy and safety evaluation of multiwavelength photobiomodulation in nonexudative age-related macular degeneration using the Lumithera Valeda Light Delivery System: 13-month results from the LIGHTSITE III trial

Key Points

• Efficacy results show significant improvements in visual function after 13 months of treatment.
• Safety evaluation indicates a low incidence of adverse events, with minimal side effects reported.
• Assessment using the Lumithera Valeda Light Delivery System provides innovative treatment for retinal health.
• Findings highlight the importance of this approach for nonexudative age-related macular degeneration patients.